Roshan Goswami | Novartis Vaccines (original) (raw)
Papers by Roshan Goswami
Journal of advances in medicine and medical research, Apr 17, 2024
Background: Fistulizing Crohn's Disease (FCD) is a distinct and aggressive subset of Crohn's Dise... more Background: Fistulizing Crohn's Disease (FCD) is a distinct and aggressive subset of Crohn's Disease, contributing to substantial morbidity, hospitalizations, and reduced patient well-being. The intricate interplay of factors influencing FCD outcomes warrants an in-depth exploration to refine patient care and therapeutic strategies. The aim of this paper is to conduct a comprehensive systematic review to critically evaluate the effectiveness, safety, and cost-effectiveness of biologic therapies and other interventions for FCD Methods: In line with the PRISMA Statement 2020 guidelines, we conducted a systematic review. We extensively searched databases including PubMed, Embase, and Cochrane Library, with the last search update on November 5, 2023. Studies evaluating FCD patients were examined, emphasizing the disease's clinical burden and influential parameters. Observational studies that underlined treatments and various FCD management strategies correlating with clinical outcomes were primarily considered for inclusion. Results: Beginning with an initial review of 438 studies, ten met the inclusion criteria and were incorporated into this systematic review. A total of 1122 patients were included. Spanning the years 2014-2022, the incorporated studies delve into diverse FCD treatment modalities. These range from the use of anti-TNF agents, surgical procedures, stem cell therapies, drug amalgamations, to intensifying dosing regimens. The synthesized findings from these studies carve out a progressively evolving treatment milieu for Crohn's disease, emphasizing the indispensability of individualized and empirically supported therapeutic avenues. Conclusion: FCD presents a formidable challenge in the realm of inflammatory bowel diseases, impacting patient outcomes. This review accentuates the pivotal nature of comprehensive care, early intervention, and addressing intricate disease mechanisms. The collated evidence highlights an imperative for innovative care modalities, targeted therapeutic endeavors, and tailored interventions to manage FCD more effectively and improve patient prognosis.
European Journal of Pharmaceutics and Biopharmaceutics, Nov 1, 2013
In this study, the efficacy of mucoadhesive polymers, i.e., chitosan and glycol chitosan as a muc... more In this study, the efficacy of mucoadhesive polymers, i.e., chitosan and glycol chitosan as a mucoadhesive coating material in nasal vaccine delivery was investigated. The Hepatitis B surface Antigen (HBsAg) encapsulated PLGA, chitosan coated PLGA (C-PLGA), and Glycol chitosan coated PLGA (GC-PLGA) nanoparticles (NPs) were prepared. The formulations were characterized for particle size, shape, surface charge, and entrapment efficiency. The mucoadhesive ability of coated and non-coated NPs was determined using in vitro mucoadhesion and nasal clearance test. In addition, the systemic uptake and bio-distribution were also evaluated to understand the fate of NPs following nasal delivery. The immuno-adjuvant ability of various formulations was compared by measuring specific antibody titer in serum and secretory. The results indicated that PLGA NPs exhibit negative surface charge, whereas C-PLGA and GC-PLGA NPs exhibited positive surface charge. The GC-PLGA NPs demonstrated lower clearance and better local and systemic uptake compared to chitosan coated and uncoated PLGA NPs. In vivo immunogenicity studies indicated that GC-PLGA NPs could induce significantly higher systemic and mucosal immune response compared to PLGA and C-PLGA NPs. In conclusion, GC-PLGA NPs could be a promising carrier adjuvant for the nasal vaccine delivery for inducing a potent immune response at mucosal surface(s) and systemic circulation.
Cellular Oncology
Background Exosomes are nanosized bio vesicles formed when multivesicular bodies and the plasma m... more Background Exosomes are nanosized bio vesicles formed when multivesicular bodies and the plasma membrane merge and discharge into bodily fluids. They are well recognized for facilitating intercellular communication by transporting numerous biomolecules, including DNA, RNAs, proteins, and lipids, and have been implicated in varied diseases including cancer. Exosomes may be altered to transport a variety of therapeutic payloads, including as short interfering RNAs, antisense oligonucleotides, chemotherapeutic drugs, and immunological modulators, and can be directed to a specific target. Exosomes also possess the potential to act as a diagnostic biomarker in cancer, in addition to their therapeutic potential. Conclusion In this review, the physiological roles played by exosomes were summarized along with their biogenesis process. Different isolation techniques of exosomes including centrifugation-based, size-based, and polymer precipitation-based techniques have also been described in detail with a special focus on cancer therapeutic applications. The review also shed light on techniques of incubation of drugs with exosomes and their characterization methods covering the most advanced techniques. Myriad applications of exosomes in cancer as diagnostic biomarkers, drug delivery carriers, and chemoresistancerelated issues have been discussed at length. Furthermore, a brief overview of exosome-based anti-cancer vaccines and a few prominent challenges concerning exosomal delivery have been concluded at the end. Keywords Exosomes • cancer • Biomarkers • Isolation • Biogenesis Abbreviations ABCA-3 ATP binding cassette transporter-A3 ABCG-2 ATP binding cassette transporter-G2 AFM Atomic force microscopy AHSG Alpha-2-HS-glycoprotein CA-125 Cancer antigen-125 CAS-9 CRISPR associated protein 9 CIB1 Cryptochrome interacting basic helix-loop-helix1 CLIC/GEEC CDC-42 dependent clathrin-independent carrier /GPI-APenriched compartment
Pharmaceutics
Lipid nanoparticles (LNP) have gained much attention after the approval of mRNA COVID-19 vaccines... more Lipid nanoparticles (LNP) have gained much attention after the approval of mRNA COVID-19 vaccines. The considerable number of currently ongoing clinical studies are testament to this fact. These efforts towards the development of LNPs warrant an insight into the fundamental developmental aspects of such systems. In this review, we discuss the key design aspects that confer efficacy to a LNP delivery system, i.e., potency, biodegradability, and immunogenicity. We also cover the underlying considerations regarding the route of administration and targeting of LNPs to hepatic and non-hepatic targets. Furthermore, since LNP efficacy is also a function of drug/nucleic acid release within endosomes, we take a holistic view of charged-based targeting approaches of LNPs not only in the context of endosomal escape but also in relation to other comparable target cell internalization strategies. Electrostatic charge-based interactions have been used in the past as a potential strategy to enhanc...
Goswami, Usha. Cognitive development : the learning brain / Usha Goswami. p. cm. Includes bibliog... more Goswami, Usha. Cognitive development : the learning brain / Usha Goswami. p. cm. Includes bibliographical references and index.
Pharmaceuticals
According to a 2020 World Health Organization report (Globocan 2020), cancer was a leading cause ... more According to a 2020 World Health Organization report (Globocan 2020), cancer was a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The aim of anticancer therapy is to specifically inhibit the growth of cancer cells while sparing normal dividing cells. Conventional chemotherapy, radiotherapy and surgical treatments have often been plagued by the frequency and severity of side effects as well as severe patient discomfort. Cancer targeting by drug delivery systems, owing to their selective targeting, efficacy, biocompatibility and high drug payload, provides an attractive alternative treatment; however, there are technical, therapeutic, manufacturing and clinical barriers that limit their use. This article provides a brief review of the challenges of conventional anticancer therapies and anticancer drug targeting with a special focus on liposomal drug delivery systems.
Pharmaceutics
Recent approval of mRNA vaccines to combat COVID-19 have highlighted the potential of this platfo... more Recent approval of mRNA vaccines to combat COVID-19 have highlighted the potential of this platform. Lipid nanoparticles (LNP) is the delivery vehicle of choice for mRNA as they prevent its enzymatic degradation by encapsulation. We have recently shown that surface exposition of mannose, incorporated in LNPs as stable cholesterol-amine conjugate, enhances the potency of self-amplifying RNA (SAM) replicon vaccines through augmented uptake by antigen presenting cells (APCs). Here, we generated a new set of LNPs whose surface was modified with mannans of different length (from mono to tetrasaccharide), in order to study the effect on antibody response of model SAM replicon encoding for the respiratory syncytial virus fusion F protein. Furthermore, the impact of the mannosylated liposomal delivery through intradermal as well as intramuscular routes was investigated. The vaccine priming response showed to improve consistently with increase in the chain length of mannoses; however, the bo...
European Journal of Pharmaceutics and Biopharmaceutics, 2013
European Journal of Pharmaceutics and Biopharmaceutics, 2013
Journal of advances in medicine and medical research, Apr 17, 2024
Background: Fistulizing Crohn's Disease (FCD) is a distinct and aggressive subset of Crohn's Dise... more Background: Fistulizing Crohn's Disease (FCD) is a distinct and aggressive subset of Crohn's Disease, contributing to substantial morbidity, hospitalizations, and reduced patient well-being. The intricate interplay of factors influencing FCD outcomes warrants an in-depth exploration to refine patient care and therapeutic strategies. The aim of this paper is to conduct a comprehensive systematic review to critically evaluate the effectiveness, safety, and cost-effectiveness of biologic therapies and other interventions for FCD Methods: In line with the PRISMA Statement 2020 guidelines, we conducted a systematic review. We extensively searched databases including PubMed, Embase, and Cochrane Library, with the last search update on November 5, 2023. Studies evaluating FCD patients were examined, emphasizing the disease's clinical burden and influential parameters. Observational studies that underlined treatments and various FCD management strategies correlating with clinical outcomes were primarily considered for inclusion. Results: Beginning with an initial review of 438 studies, ten met the inclusion criteria and were incorporated into this systematic review. A total of 1122 patients were included. Spanning the years 2014-2022, the incorporated studies delve into diverse FCD treatment modalities. These range from the use of anti-TNF agents, surgical procedures, stem cell therapies, drug amalgamations, to intensifying dosing regimens. The synthesized findings from these studies carve out a progressively evolving treatment milieu for Crohn's disease, emphasizing the indispensability of individualized and empirically supported therapeutic avenues. Conclusion: FCD presents a formidable challenge in the realm of inflammatory bowel diseases, impacting patient outcomes. This review accentuates the pivotal nature of comprehensive care, early intervention, and addressing intricate disease mechanisms. The collated evidence highlights an imperative for innovative care modalities, targeted therapeutic endeavors, and tailored interventions to manage FCD more effectively and improve patient prognosis.
European Journal of Pharmaceutics and Biopharmaceutics, Nov 1, 2013
In this study, the efficacy of mucoadhesive polymers, i.e., chitosan and glycol chitosan as a muc... more In this study, the efficacy of mucoadhesive polymers, i.e., chitosan and glycol chitosan as a mucoadhesive coating material in nasal vaccine delivery was investigated. The Hepatitis B surface Antigen (HBsAg) encapsulated PLGA, chitosan coated PLGA (C-PLGA), and Glycol chitosan coated PLGA (GC-PLGA) nanoparticles (NPs) were prepared. The formulations were characterized for particle size, shape, surface charge, and entrapment efficiency. The mucoadhesive ability of coated and non-coated NPs was determined using in vitro mucoadhesion and nasal clearance test. In addition, the systemic uptake and bio-distribution were also evaluated to understand the fate of NPs following nasal delivery. The immuno-adjuvant ability of various formulations was compared by measuring specific antibody titer in serum and secretory. The results indicated that PLGA NPs exhibit negative surface charge, whereas C-PLGA and GC-PLGA NPs exhibited positive surface charge. The GC-PLGA NPs demonstrated lower clearance and better local and systemic uptake compared to chitosan coated and uncoated PLGA NPs. In vivo immunogenicity studies indicated that GC-PLGA NPs could induce significantly higher systemic and mucosal immune response compared to PLGA and C-PLGA NPs. In conclusion, GC-PLGA NPs could be a promising carrier adjuvant for the nasal vaccine delivery for inducing a potent immune response at mucosal surface(s) and systemic circulation.
Cellular Oncology
Background Exosomes are nanosized bio vesicles formed when multivesicular bodies and the plasma m... more Background Exosomes are nanosized bio vesicles formed when multivesicular bodies and the plasma membrane merge and discharge into bodily fluids. They are well recognized for facilitating intercellular communication by transporting numerous biomolecules, including DNA, RNAs, proteins, and lipids, and have been implicated in varied diseases including cancer. Exosomes may be altered to transport a variety of therapeutic payloads, including as short interfering RNAs, antisense oligonucleotides, chemotherapeutic drugs, and immunological modulators, and can be directed to a specific target. Exosomes also possess the potential to act as a diagnostic biomarker in cancer, in addition to their therapeutic potential. Conclusion In this review, the physiological roles played by exosomes were summarized along with their biogenesis process. Different isolation techniques of exosomes including centrifugation-based, size-based, and polymer precipitation-based techniques have also been described in detail with a special focus on cancer therapeutic applications. The review also shed light on techniques of incubation of drugs with exosomes and their characterization methods covering the most advanced techniques. Myriad applications of exosomes in cancer as diagnostic biomarkers, drug delivery carriers, and chemoresistancerelated issues have been discussed at length. Furthermore, a brief overview of exosome-based anti-cancer vaccines and a few prominent challenges concerning exosomal delivery have been concluded at the end. Keywords Exosomes • cancer • Biomarkers • Isolation • Biogenesis Abbreviations ABCA-3 ATP binding cassette transporter-A3 ABCG-2 ATP binding cassette transporter-G2 AFM Atomic force microscopy AHSG Alpha-2-HS-glycoprotein CA-125 Cancer antigen-125 CAS-9 CRISPR associated protein 9 CIB1 Cryptochrome interacting basic helix-loop-helix1 CLIC/GEEC CDC-42 dependent clathrin-independent carrier /GPI-APenriched compartment
Pharmaceutics
Lipid nanoparticles (LNP) have gained much attention after the approval of mRNA COVID-19 vaccines... more Lipid nanoparticles (LNP) have gained much attention after the approval of mRNA COVID-19 vaccines. The considerable number of currently ongoing clinical studies are testament to this fact. These efforts towards the development of LNPs warrant an insight into the fundamental developmental aspects of such systems. In this review, we discuss the key design aspects that confer efficacy to a LNP delivery system, i.e., potency, biodegradability, and immunogenicity. We also cover the underlying considerations regarding the route of administration and targeting of LNPs to hepatic and non-hepatic targets. Furthermore, since LNP efficacy is also a function of drug/nucleic acid release within endosomes, we take a holistic view of charged-based targeting approaches of LNPs not only in the context of endosomal escape but also in relation to other comparable target cell internalization strategies. Electrostatic charge-based interactions have been used in the past as a potential strategy to enhanc...
Goswami, Usha. Cognitive development : the learning brain / Usha Goswami. p. cm. Includes bibliog... more Goswami, Usha. Cognitive development : the learning brain / Usha Goswami. p. cm. Includes bibliographical references and index.
Pharmaceuticals
According to a 2020 World Health Organization report (Globocan 2020), cancer was a leading cause ... more According to a 2020 World Health Organization report (Globocan 2020), cancer was a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The aim of anticancer therapy is to specifically inhibit the growth of cancer cells while sparing normal dividing cells. Conventional chemotherapy, radiotherapy and surgical treatments have often been plagued by the frequency and severity of side effects as well as severe patient discomfort. Cancer targeting by drug delivery systems, owing to their selective targeting, efficacy, biocompatibility and high drug payload, provides an attractive alternative treatment; however, there are technical, therapeutic, manufacturing and clinical barriers that limit their use. This article provides a brief review of the challenges of conventional anticancer therapies and anticancer drug targeting with a special focus on liposomal drug delivery systems.
Pharmaceutics
Recent approval of mRNA vaccines to combat COVID-19 have highlighted the potential of this platfo... more Recent approval of mRNA vaccines to combat COVID-19 have highlighted the potential of this platform. Lipid nanoparticles (LNP) is the delivery vehicle of choice for mRNA as they prevent its enzymatic degradation by encapsulation. We have recently shown that surface exposition of mannose, incorporated in LNPs as stable cholesterol-amine conjugate, enhances the potency of self-amplifying RNA (SAM) replicon vaccines through augmented uptake by antigen presenting cells (APCs). Here, we generated a new set of LNPs whose surface was modified with mannans of different length (from mono to tetrasaccharide), in order to study the effect on antibody response of model SAM replicon encoding for the respiratory syncytial virus fusion F protein. Furthermore, the impact of the mannosylated liposomal delivery through intradermal as well as intramuscular routes was investigated. The vaccine priming response showed to improve consistently with increase in the chain length of mannoses; however, the bo...
European Journal of Pharmaceutics and Biopharmaceutics, 2013
European Journal of Pharmaceutics and Biopharmaceutics, 2013